118 related articles for article (PubMed ID: 35970208)
1. Predicting Visual Outcomes in Choroidal Osteoma Treated with Anti-vascular Endothelial Growth Factor.
Kang HG; Kim TY; Lee J; Byeon SH; Kim SS; Kim M
Am J Ophthalmol; 2022 Dec; 244():143-151. PubMed ID: 35970208
[TBL] [Abstract][Full Text] [Related]
2. Choroidal neovascularization due to choroidal osteoma treated with anti-vascular endothelial growth factor therapy: An optical coherence tomography angiography study.
Furino C; Di Antonio L; Grassi MO; Rispoli M; Reibaldi M; Niro A; Alessio G
Eur J Ophthalmol; 2019 May; 29(3):323-329. PubMed ID: 30101614
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma.
Khan MA; DeCroos FC; Storey PP; Shields JA; Garg SJ; Shields CL
Retina; 2014 Sep; 34(9):1750-6. PubMed ID: 24936941
[TBL] [Abstract][Full Text] [Related]
4. Complications, treatments, and visual prognosis of choroidal osteomas.
Seong HJ; Kim YJ; Choi EY; Lee J; Byeon SH; Kim SS; Koh HJ; Lee SC; Lee CS
Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1713-1721. PubMed ID: 34762167
[TBL] [Abstract][Full Text] [Related]
5. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NAIVE IDIOPATHIC CHOROIDAL NEOVASCULARIZATION: A Comparative Study.
Sudhalkar A; Yogi R; Chhablani J
Retina; 2015 Jul; 35(7):1368-74. PubMed ID: 25830696
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
7. Etiology, Treatment Patterns, and Outcomes for Choroidal Neovascularization in the Pediatric Population: An Intelligent Research in Sight (IRIS®) Registry Study.
Finn AP; Fujino D; Lum F; Rao P
Ophthalmol Retina; 2022 Feb; 6(2):130-138. PubMed ID: 34091079
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma.
Papastefanou VP; Pefkianaki M; Al Harby L; Arora AK; Cohen VM; Andrews RM; Sagoo MS
Eye (Lond); 2016 Jun; 30(6):843-9. PubMed ID: 27034203
[TBL] [Abstract][Full Text] [Related]
9. Choroidal Osteoma with Choroidal Neovascular Membrane treated with Anti- vascular Endothelial Growth Factor: A Rare Case with Review of Literatures.
Dorji P; Lepcha NT; Thapa R
Nepal J Ophthalmol; 2021 Jul; 13(24):196-201. PubMed ID: 35996784
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy combined with intravitreal bevacizumab in a patient with choroidal neovascularization secondary to choroidal osteoma.
Jang JH; Kim KH; Lee SJ; Park JM
Korean J Ophthalmol; 2012 Dec; 26(6):478-80. PubMed ID: 23204807
[TBL] [Abstract][Full Text] [Related]
11. Optical Coherence Tomography Angiography for Detecting Choroidal Neovascularization Secondary to Choroidal Osteoma.
Szelog JT; Bonini Filho MA; Lally DR; de Carlo TE; Duker JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Jan; 47(1):69-72. PubMed ID: 26731212
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal Antivascular Endothelial Growth Factor Treatment for Inflammatory Choroidal Neovascularization in Noninfectious Uveitis.
Woronkowicz M; Niederer R; Lightman S; Tomkins-Netzer O
Am J Ophthalmol; 2022 Apr; 236():281-287. PubMed ID: 34289337
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.
Lai TY; Luk FO; Lee GK; Lam DS
Eye (Lond); 2012 Jul; 26(7):1004-11. PubMed ID: 22595908
[TBL] [Abstract][Full Text] [Related]
14. INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN ANGIOID STREAKS: Four-Year Follow-up.
Tilleul J; Mimoun G; Querques G; Puche N; Zerbib J; Lalloum F; Srour M; Souied EH
Retina; 2016 Mar; 36(3):483-91. PubMed ID: 26355947
[TBL] [Abstract][Full Text] [Related]
15. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to traumatic choroidal rupture.
Barth T; Zeman F; Helbig H; Gamulescu MA
BMC Ophthalmol; 2019 Nov; 19(1):239. PubMed ID: 31771544
[TBL] [Abstract][Full Text] [Related]
17. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous Resolution of Subretinal Detachment in Choroidal Osteoma Unresponsive to Antivascular Endothelial Growth Factor Agent and Multimodal Imaging: A Case Report.
Lee HJ; Woo SJ
Korean J Ophthalmol; 2023 Feb; 37(1):82-84. PubMed ID: 36796349
[No Abstract] [Full Text] [Related]
19. Intravitreal bevacizumab in the management of choroidal neovascular membrane secondary to choroidal osteoma.
Narayanan R; Shah VA
Eur J Ophthalmol; 2008; 18(3):466-8. PubMed ID: 18465736
[TBL] [Abstract][Full Text] [Related]
20. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
Rahimy E; Rayess N; Ho AC; Regillo CD
Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
